Latest Breaking News On - Early drug development - Page 3 : comparemela.com

The Menarini Group: European Commission Approves Menarini Group s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

The Menarini Group: European Commission Approves Menarini Group s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergElcin barker ergunGiuseppe curiglianoValeria speroni cardiCheya popeStemline therapeutics incUniversity of milanoMenarini groupWorld health organization globocanRadius health incEuropean medicines agencyInternational agency for research on cancerEuropean institute of oncologyEuropean commissionStemline therapeutics

European Commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer

The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor.

San antonioUnited statesElcin barker ergunGiuseppe curiglianoEuropean institute of oncologyDivision of early drug developmentEuropean commissionMenarini groupUniversity of milanoBarker ergunAntonio breast cancer symposiumEarly drug developmentEuropean instituteEstrogen receptor positiveHer2 negativeLocally advanced

Menarini Industrie Farmaceutiche Riunite: European Commission Approves Menarini Group s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Menarini Industrie Farmaceutiche Riunite: European Commission Approves Menarini Group s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesBaden wübergGiuseppe curiglianoElcin barker ergunStemline therapeutics incMenarini groupUniversity of milanoEuropean medicines agencyWorld health organizationEuropean commissionInternational agency for research on cancerEuropean institute of oncologyRadius health incStemline therapeuticsMedicinal productsHuman use

European Commission Approves Menarini Group s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000.

United statesMenarini industrie farmaceutiche riuniteElcin barker ergunGiuseppe curiglianoMenarini groupStemline therapeutics incWorld health organizationUniversity of milanoEuropean medicines agencyInternational agency for research on cancerRadius health incEuropean institute of oncologyEuropean commissionStemline therapeuticsMedicinal productsHuman use

40% of Global AI Companies Focus on Early Drug Development while AI-Powered Startups Reshape the Future of Drug Discovery

40% of Global AI Companies Focus on Early Drug Development while AI-Powered Startups Reshape the Future of Drug DiscoveryNew industry report from Deep Pharma Intelligence has redefined the Global State of AI in Drug DiscoveryAugust 16, 2023 - London, UK: The largest profiling of the global AI in the Drug Discovery i.

United kingdomCity ofAndrey savitskiyKnowledge groupEarly drug developmentPowered startups reshapeDrug discoveryDeep pharma intelligenceGlobal stateBig pharmaDrug discovery expertsBig data analytics systemDrug discovery industryCancer vaccinesPharma intelligenceDeep knowledge group